 Antitubercular Agents
"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 0 | 3 | | 2004 | 3 | 1 | 4 | | 2005 | 2 | 1 | 3 | | 2006 | 2 | 3 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 8 | 4 | 12 | | 2012 | 7 | 5 | 12 | | 2013 | 5 | 0 | 5 | | 2014 | 6 | 4 | 10 | | 2015 | 2 | 1 | 3 | | 2016 | 6 | 5 | 11 | | 2017 | 2 | 0 | 2 | | 2018 | 6 | 4 | 10 | | 2019 | 7 | 2 | 9 | | 2020 | 2 | 3 | 5 | | 2021 | 2 | 6 | 8 | | 2022 | 0 | 2 | 2 | | 2023 | 2 | 6 | 8 | | 2024 | 4 | 2 | 6 | | 2025 | 8 | 0 | 8 | | 2026 | 9 | 0 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Hendrix J, Al Mubarak R, Reichlen MJ, Tabor ST, Bateman A, Massoudi LM, Rossmassler K, Kaya F, Zimmerman MD, Nielsen H, Wynn EA, Voskuil MI, Robertson GT, Moore CM, Walter ND. Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo. PLoS Pathog. 2026 Apr; 22(4):e1014131.
-
Mpofu R, Chandiwana N, Sokhela S, Moorhouse M, Venter F, Anderson PL, Wiesner L, Boffito M, Maartens G, Sinxadi P. The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis. J Acquir Immune Defic Syndr. 2026 Apr 01; 101(4):424-431.
-
Yengkhom D, Montepiedra G, Masheto G, Wabwire D, Stranix-Chibanda L, Matubu A, Violari A, Theron G, Gupta A, Weinberg A. Tuberculosis preventive therapy in postpartum women with HIV modifies M. tuberculosis-specific and nonspecific immune responses. Front Immunol. 2026; 17:1722621.
-
Béranger A, Solans BP, Miyakawa R, McIlleron H, Tarning J, Shah I, Aruldhas BW, Mathew BS, Kwara A, Peloquin CA, Mukherjee A, Lodha R, Denti P, Capparelli EV, Kiser JJ, Bekker A, Chabala C, Choo L, Turkova A, Gafar F, Ruslami R, Nataprawira HM, Heysell SK, Thomas TA, Velpandian T, Day JN, Bang ND, Dooley K, Savic RM. Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis. Eur Respir J. 2026 Mar; 67(3).
-
Riedel C, Rahkola J, Reichlen M, Ries H, Ericksen SS, Voskuil M, Gitter A, Wlodarchak N. Identification and characterization of inhibitors of the tuberculosis phosphatase PstP. J Biol Chem. 2026 Apr; 302(4):111316.
-
Meena S, Fatima F, Qais FA, Ramachandran S. Computational screening of natural plant and marine compounds as potential inhibitors of Mycobacterium tuberculosis dihydrodipicolinate synthase. Comput Biol Chem. 2026 Jun; 122:108936.
-
Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Wabwire D, Masheto G, Jean-Philippe P, Sterling TR, Weinberg A, Gupta A. Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics. Clin Infect Dis. 2026 Feb 09; 82(1):e156-e164.
-
Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26.
-
Sordello S, Brock L, Tagliavini A, Federico D, Boulenc X, Pergher M, Huc Claustre E, Metcalf D, Walter ND, Robertson GT, Clary J, Berg A, Mdluli K, Hermann D, Flood D, Upton AM. A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model. Antimicrob Agents Chemother. 2026 Feb 04; 70(2):e0110925.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Hendrix J, Voskuil MI, Obregón-Henao A, Lyons MA, Robertson GT, Moore CM, Walter ND. Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo. Antimicrob Agents Chemother. 2025 Nov 05; 69(11):e0049225.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|